BRPI0412760A - uso de um inibidor de pak para o tratamento de uma doença de articulação - Google Patents

uso de um inibidor de pak para o tratamento de uma doença de articulação

Info

Publication number
BRPI0412760A
BRPI0412760A BRPI0412760-9A BRPI0412760A BRPI0412760A BR PI0412760 A BRPI0412760 A BR PI0412760A BR PI0412760 A BRPI0412760 A BR PI0412760A BR PI0412760 A BRPI0412760 A BR PI0412760A
Authority
BR
Brazil
Prior art keywords
joint disease
pak
pak inhibitor
treat joint
treatment
Prior art date
Application number
BRPI0412760-9A
Other languages
English (en)
Inventor
Sebastian Barradeau
Eckart Bartnik
Joerg Czech
Andreas R Klatt
Ekkehard Leberer
Thomas Leeuw
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BRPI0412760A publication Critical patent/BRPI0412760A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

"USO DE UM INIBIDOR DE PAK PARA O TRATAMENTO DE UMA DOENçA DE ARTICULAçãO". A presente invenção refere-se ao uso de um inibidor de cinase ativada por p21 (PAK) para o tratamento de uma doença de articulação como osteoartrite ou artrite reumatóide ou para o tratamento de uma dor de articulação e ao uso de PAK como uma proteína alvo para a descoberta de um inibidor de PAK como um medicamento para o tratamento de uma doença de articulação.
BRPI0412760-9A 2003-07-18 2004-07-15 uso de um inibidor de pak para o tratamento de uma doença de articulação BRPI0412760A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03016303A EP1498133A1 (en) 2003-07-18 2003-07-18 Use of a pak inhibitor for the treatment of a joint disease
PCT/EP2004/007855 WO2005011721A2 (en) 2003-07-18 2004-07-15 Use of a pak inhibitor for the treatment of a joint disease

Publications (1)

Publication Number Publication Date
BRPI0412760A true BRPI0412760A (pt) 2006-09-26

Family

ID=33462155

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412760-9A BRPI0412760A (pt) 2003-07-18 2004-07-15 uso de um inibidor de pak para o tratamento de uma doença de articulação

Country Status (14)

Country Link
EP (3) EP1498133A1 (pt)
JP (1) JP4843487B2 (pt)
KR (2) KR101238755B1 (pt)
CN (1) CN1826130B (pt)
AU (1) AU2004260590B2 (pt)
BR (1) BRPI0412760A (pt)
CA (1) CA2532742C (pt)
HK (1) HK1096854A1 (pt)
IL (3) IL173145A (pt)
MX (1) MXPA06000637A (pt)
NO (1) NO20060808L (pt)
RU (1) RU2360696C2 (pt)
WO (1) WO2005011721A2 (pt)
ZA (1) ZA200510377B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
EP1955071A4 (en) 2005-10-28 2009-03-18 Invitrogen Corp ASSAYS OF ACTIVITY KINASE AND UBIQUITINATION
AU2007208213A1 (en) * 2006-01-24 2007-08-02 University Of Virginia Patent Foundation Compositions and methods for inhibition leukocyte function
KR100835795B1 (ko) * 2006-11-17 2008-06-09 김응국 키나아제 팩2의 활성을 저해하는 펩타이드
CA2732715C (en) 2008-08-01 2015-04-07 Kusuki Nishioka Treatment agent or preventative agent for osteoarthritis
GB0814570D0 (en) * 2008-08-08 2008-09-17 Diagnostics For The Real World Isolation of nucleic acid
US8513308B2 (en) 2008-08-08 2013-08-20 The Board Of Trustees Of The University Of Illinois PAK1 agonists and methods of use
US8663930B2 (en) * 2009-04-01 2014-03-04 Galapagos Nv Methods and means for treatment of osteoarthritis
JP2012246222A (ja) 2010-01-29 2012-12-13 Axis Inc 変形性関節症治療剤または予防剤を製造するための使用
CA2788527A1 (en) 2010-01-29 2011-08-04 Axis Inc. Pharmaceutical composition for osteoarthritis treatment or prevention and manufacturing method therefor
CN102821786B (zh) 2010-01-29 2016-01-13 阿克西斯股份有限公司 含有骨关节炎治疗剂的注射液
EP3630178A1 (en) * 2017-06-02 2020-04-08 Merck Patent GmbH Mmp13 binding immunoglobulins
CN114042053B (zh) * 2021-10-25 2023-07-25 北京理工大学 siRNA输送载体及其制备方法和应用
WO2023097475A1 (zh) * 2021-11-30 2023-06-08 绍兴守仁医疗健康科技有限公司 人pak1蛋白的真核表达载体的构建方法、表达和纯化方法
CN114767864B (zh) * 2022-05-10 2023-05-12 天津医科大学总医院 Pak3抑制剂在治疗瑞芬太尼诱发的切口痛觉过敏中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5582981A (en) 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
DK0605522T3 (da) 1991-09-23 2000-01-17 Medical Res Council Fremgangsmåde til fremstilling af humaniserede antistoffer
CA2174339A1 (en) 1993-10-27 1995-05-04 Lech W. Dudycz 2'-amido and 2'-peptido modified oligonucleotides
US5518911A (en) * 1995-01-06 1996-05-21 Onyx Pharmaceuticals, Inc. Human PAK65
FR2739031B1 (fr) 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique
GB9602326D0 (en) 1996-02-06 1996-04-03 Cruachem Ltd Compounds
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
NZ332033A (en) 1996-03-25 1999-09-29 Lohmann Therapie Syst Lts Transdermal therapeutic system (tts) with small application-area thickness and great flexibility, and production process
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
EP1007735A1 (en) 1997-02-24 2000-06-14 TM Technologies Inc. Anti-sense oligonucleotide pharmacological agents
US6383734B1 (en) * 1998-09-30 2002-05-07 Advanced Research And Technology Institute, Inc. Method to determine inhibition of PAK3 activation of Raf-1
AU3566200A (en) * 1999-04-01 2000-10-23 Astrazeneca Uk Limited Human signal transduction serine/threonine protein kinase

Also Published As

Publication number Publication date
RU2006105013A (ru) 2006-06-27
IL204861A (en) 2011-09-27
ZA200510377B (en) 2006-10-25
IL173145A (en) 2010-12-30
HK1096854A1 (en) 2007-06-15
CA2532742A1 (en) 2005-02-10
IL173145A0 (en) 2006-06-11
KR20120034250A (ko) 2012-04-10
WO2005011721A3 (en) 2005-04-21
CN1826130B (zh) 2012-08-29
CA2532742C (en) 2013-07-09
KR101238755B1 (ko) 2013-03-07
KR20060052832A (ko) 2006-05-19
CN1826130A (zh) 2006-08-30
MXPA06000637A (es) 2006-08-23
NO20060808L (no) 2006-04-12
AU2004260590B2 (en) 2010-06-03
JP4843487B2 (ja) 2011-12-21
EP1498133A1 (en) 2005-01-19
WO2005011721A2 (en) 2005-02-10
EP1648486A2 (en) 2006-04-26
IL198727A (en) 2011-03-31
RU2360696C2 (ru) 2009-07-10
EP2275116A1 (en) 2011-01-19
JP2007537134A (ja) 2007-12-20
AU2004260590A1 (en) 2005-02-10
KR101299936B1 (ko) 2013-08-26

Similar Documents

Publication Publication Date Title
BRPI0412760A (pt) uso de um inibidor de pak para o tratamento de uma doença de articulação
BRPI0407919A (pt) pirrolopirimidinas espiro-substituìdas
BR0315164A (pt) Métodos para tratar dor pós-cirúrgica administrando um antagonista de fator de crescimento nervoso e composições contendo o mesmo
DE60216139D1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
BRPI0508390A (pt) métodos para tratamento de dor de cáncer de osso através da administração de um antagonista de fator de crescimento de nervo
BR112018070586A2 (pt) compostos de pirazol[1,5-a]pirimidinil carboxamida e seu uso no tratamento de distúrbios médicos
BRPI0607897A2 (pt) compostos oxindol e sua utilização como agentes terapêuticos
ATE395871T1 (de) Marknagel zur behandlung von proximalen oberschenkelknochenbrüchen
EA200600048A1 (ru) Производные бензазепина, используемые для лечения заболеваний, ассоциированных с 5-ht-рецептором
TW200724543A (en) Heterocyclic compounds and their uses as therapeutic agents
MX2010005651A (es) Inhibicion de receptor de proteina de estimulacion de macrofagos (ron) y sus metodos de tratamiento.
EA200702212A1 (ru) Способ лечения или профилактики разрушения кости или остеопороза
RS51069B (sr) Upotreba oksikodona za tretiranje visceralnog bola
MX2009013766A (es) Objetivos moleculares y compuestos, y metodos para identificar los mismos, utiles en el tratamiento de enfermedades degenerativas de los huesos y las articulaciones.
GB0623258D0 (en) Thiadiazole derivatives for the treatment of neuro-degenerative diseases
EP1461313A4 (en) INHIBITORS OF HUMAN ADAM-10
EA201400423A1 (ru) Фармацевтические препараты и их применение при лечении половой дисфункции у женщин
BRPI0606898A2 (pt) uso de agonista de 5-ht4 na preparação de medicamentos e método útil no esvaziamento gástrico retardado
EA200702311A1 (ru) Фосфонированные фторхинолоны, их антибактериальные аналоги и способы профилактики и лечения инфекций костей и суставов
BR112022009066A2 (pt) Ezetimiba para uso em tratamento de câncer
ATE401888T1 (de) Verwendung von tigecyclin, allein oder in kombination mit rifampin zur behandlung von osteomyelitis und/oder septischer arthritis
CY1110156T1 (el) Υποκατεστημενες ενωσεις 4,5,6,7-τετραϋδρο-βενζοθειαζολ-2-υλαμινης
BR0309412A (pt) Indol-2-onas como inibidores seletivos da ciclooxigenase-2
EP1620061A4 (en) ANTIVIRAL AGENTS FOR THE TREATMENT, CONTROL AND PREVENTION OF INFECTIONS BY CORONAVIRES
WO2004087905A3 (en) Protein tyrosine phosphatase and inhibitors thereof

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 12A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]